CVI Holdings’s BioXcel Therapeutics BTAI Stock Holding History

CVI Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,937	Closed	-$1.12M	–	38
2019 Q3	$1.12M	Buy	+9,937	New	+$1.57M	2.51%	11

Other funds holding BTAI

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CVI Holdings's BTAI Position: Q4 2019 in Review

CVI Holdings sold out of BioXcel Therapeutics (BTAI) in Q4 2019, closing a stake of 9,937 shares — an estimated $1.12M sold.

CVI Holdings first reported a position in BTAI in Q3 2019 and held it in 1 quarter. The position peaked at $1.12M in Q3 2019. 43 funds tracked by Wall St. Rank hold BTAI as of Q4 2019.

CVI Holdings reported no remaining BioXcel Therapeutics position as of Q4 2019 after selling out during the quarter.
CVI Holdings sold 9,937 BioXcel Therapeutics shares in Q4 2019, an estimated $1.12M.
CVI Holdings first reported a position in BioXcel Therapeutics in Q3 2019 and held it in 1 quarter.
CVI Holdings's BioXcel Therapeutics position peaked at $1.12M in Q3 2019.
43 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2019.

Based on CVI Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.